首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1701447

血浆分馏市场规模、份额、成长分析（按产品、应用、最终用户、地区）- 2025 年至 2032 年产业预测

Plasma Fractionation Market Size, Share, and Growth Analysis, By Product (Immunoglobulins, Coagulation Factor Concentrates), By Application (Neurology, Immunology), By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月01日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023 年全球血浆分馏市场规模价值为 334.3 亿美元，预计将从 2024 年的 362 亿美元成长到 2032 年的 685.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.3%。

全球血浆分馏市场预计将经历显着增长，主要原因是人口老化，导致人们越来越容易患上需要血浆疗法治疗的罕见疾病。血浆分馏涉及分离血浆以生产重要产品，例如免疫球蛋白和第八因子，这些产品对于治疗血友病和免疫力缺乏等疾病至关重要。这些治疗应用的日益普及以及血浆采集设施的激增进一步推动了市场扩张。此外，政府为提高人们对血浆衍生产品的认识而采取的措施也促进了市场的动态。然而，这些血浆衍生物的高成本带来了越来越大的挑战，凸显了製定策略来提高医疗保健环境中的可负担性和可近性的必要性。

市场概览
免疫球蛋白
- 静脉注射免疫球蛋白
- 皮下注射免疫球蛋白
- 其他免疫球蛋白
凝血因子浓缩物
- 第八因子
- 凝血因子IX
- 血管性血友病因子
- 凝血酶原复合物浓缩物
- 纤维蛋白原浓缩物
- 因子 XIII
- 其他凝血因子浓缩物
白蛋白
蛋白酶抑制剂
其他血浆产品

血浆分馏市场规模（依应用）及复合年增长率（2025-2032）

市场概览
神经病学
免疫学
血液学
加护治疗
呼吸系统医疗设备
血液学/肿瘤学
风湿病学
其他用途

血浆分馏市场规模（依最终用户划分）及复合年增长率（2025-2032）

市场概览
医院和诊所
临床研究实验室
学术机构

血浆分馏市场规模（按地区）及复合年增长率（2025-2032）

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

Grifols, SA（Spain）
Takeda Pharmaceutical Company Limited（Japan）
Octapharma AG（Switzerland）
Kedrion SpA（Italy）
Biotest AG（Germany）
LFB SA（France）
Sanquin Blood Supply Foundation（Netherlands）
China National Biotec Group Company Limited（China）
ADMA Biologics, Inc.（USA）
GC Biopharma Corp.（South Korea）
Hualan Biological Bacterin Inc.（China）
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
Shanghai RAAS Blood Products Co., Ltd.（China）

主要进展

Bio Products Laboratory Ltd (UK)
Green Cross Corporation (South Korea)
TianTan Biological Products Corporation Limited (China)
Emergent BioSolutions Inc. (USA)
Kamada Ltd. (Israel)

结论和建议

简介目录

Product Code: SQMIG35H2165

Global Plasma Fractionation Market size was valued at USD 33.43 billion in 2023 and is poised to grow from USD 36.2 billion in 2024 to USD 68.52 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global plasma fractionation market is poised for significant growth, primarily driven by an aging population that is increasingly susceptible to rare diseases requiring plasma-derived treatments. Plasma fractionation involves separating blood plasma to produce vital products such as immunoglobulins and factor VIII, which are critical in treating conditions like hemophilia and immunological deficiencies. The rising prevalence of these therapeutic applications, alongside a surge in plasma collection facilities, further propels market expansion. Additionally, government initiatives aimed at increasing awareness about plasma-derived products are contributing to market dynamics. However, the high cost associated with these plasma derivatives poses a challenge to growth, underscoring the need for strategies that enhance affordability and accessibility in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segments Analysis

Global Plasma Fractionation Market is segmented by Product, Application, End User and region. Based on Product, the market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Plasma Products. Based on Application, the market is segmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, Hemato-Oncology, Rheumatology and Other Applications. Based on End User, the market is segmented into Hospitals and Clinics, Clinical Research Laboratories and Academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Fractionation Market

The increasing prevalence of diseases associated with immunodeficiency disorders and autoimmune conditions is a significant factor driving the expansion of the global plasma fractionation market. As healthcare professionals increasingly rely on immunoglobulins to treat these conditions, the demand for such products has surged. This rising demand not only propels growth in the market but also fosters innovation in the purification processes and manufacturing of plasma-derived therapeutic products. Consequently, this trend emphasizes the necessity for advancements in plasma fractionation technologies, further contributing to the development of effective treatments for patients suffering from these complex health issues.

Restraints in the Global Plasma Fractionation Market

The Global Plasma Fractionation market faces significant constraints stemming from the economic awareness of industry participants, which can lead to the establishment of barriers to entry in regions lacking support for economic growth. High costs associated with the plasma fractionation process, driven by sophisticated technology and stringent regulations, pose a challenge. These expenses create a barrier to market comprehension, particularly for smaller companies, hampering their potential for expansion. This situation is particularly pronounced in price-sensitive regions, where the financial burden can restrict participation and limit opportunities for development in the plasma fractionation sector.

Market Trends of the Global Plasma Fractionation Market

The global plasma fractionation market is witnessing significant growth driven by the surging demand for specialized plasma-derived products such as immunoglobulins and clotting factor concentrates. This trend is largely fueled by the rising prevalence of chronic and autoimmune diseases, prompting healthcare systems to seek more effective and targeted treatment solutions. Additionally, advancements in fractionation technologies and an expanding patient population are further propelling market expansion. As awareness of plasma-based therapies increases, stakeholders in this sector are investing in research and development to enhance product efficacy and safety, positioning the global plasma fractionation market for robust growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Plasma Fractionation Market Size by Product & CAGR (2025-2032)

Market Overview
Immunoglobulins
- Intravenous Immunoglobulins
- Subcutaneous Immunoglobulins
- Other Immunoglobulins
Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrate
- Fibrinogen Concentrates
- Factor XIII
- Other Coagulation Factor Concentrates
Albumin
Protease Inhibitors
Other Plasma Products

Global Plasma Fractionation Market Size by Application & CAGR (2025-2032)

Market Overview
Neurology
Immunology
Hematology
Critical care
Pulmonology
Hemato-Oncology
Rheumatology
Other Applications

Global Plasma Fractionation Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

Global Plasma Fractionation Market Size & CAGR (2025-2032)

North America (Product, Application, End User)
- US
- Canada
Europe (Product, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin Blood Supply Foundation (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China National Biotec Group Company Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GC Biopharma Corp. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hualan Biological Bacterin Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates

Key Developments

Bio Products Laboratory Ltd (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TianTan Biological Products Corporation Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments